Lowest Price Guaranteed From USD 5,899
Published
January 2021
Pages
272
View Count
8737
Example Insights
-thumb.PNG) |
 |
 |
-thumb.PNG) |
-thumb.PNG) |
-thumb.PNG) |
 |
-thumb.PNG) |
 |
 |
 |
Report Description
From periodically monitoring disease progression in patients to developing customized therapies based on genetic predisposition, biomarkers (which are specific indicators of biological events) have become an indispensable aspect of contemporary healthcare solutions / practices. Ongoing digitization efforts in the healthcare industry have led to the development of a number of digital solutions, which are capable of generating, collecting, and tracking medical data. From this data, details of anatomical, physiological, and molecular events, and even behavior-related patterns in humans, or digital biomarkers, have been acknowledged as viable inputs to explain, influence and / or predict health-related outcomes. Digital biomarkers are analyzed in silico, using advanced analytical algorithms and artificial intelligence (AI) enabled tools, and therefore, can be used to rapidly generate actionable insights and identify previously undetected biological events (obscured by the shortcomings of manual processes). In this context, regulatory bodies across the world have actually begun evaluating software as a medical device. Fundamentally, digital biomarkers are identified / measured using sensors and algorithms across the plethora of available connected medical devices and other health-focused software solutions. Moreover, the fact that the procurement / analysis of digital biomarkers are not limited to the physical confines of the clinical environment, presents new opportunities to revolutionize disease diagnosis, patient monitoring and clinical trial conduct. When combined with specific phenotypic signatures, digital biomarkers have demonstrated the potential to be used to generate insights related to esoteric medical fields, such as psychiatry and neurology. In fact, experts believe that future diagnostic / treatment protocols for certain mental health indications are likely to be underpinned by digital biomarkers, similar to how the management of diabetes and hypertension are underpinned by biochemical biomarkers.
In the current pandemic scenario, medical professionals are trying to identify digital biomarkers that can facilitate the successful screening / diagnosis of COVID-19 patients, remotely. For instance, the National Institutes of Health (NIH) has tasked physIQ with developing and validating an algorithm, which can use existing wearable biosensor-derived analytics (generated by the company’s pinpointIQ™ cloud platform) to discover a novel digital biomarker for COVID-19 associated decompensation. In this regard, it is worth noting that the development of tools to capture digital biomarkers and analyze them, requires multidisciplinary (including computer science and engineering, as well as neology and medicine) expertise. Currently, several successful start-ups claim to be involved in designing and developing the necessary software / hardware solutions for the abovementioned purposes. Most of these companies have also received significant capital investments to support their respective product development initiatives. One of the primary challenges encountered by innovators in this market is related to regulatory review. Digital biomarkers are subjected to the same level of regulatory scrutiny as their traditional counterparts. Moreover, there is an evident need for a systematic approach to assess the quality and utility of digitized renderings of biological events, in order to gauge their safety and efficacy in informing health-related decision making. Despite existing challenges, this niche, but emerging domain, is expected to evolve complementary to digital therapeutics, with pioneers in the field poised to benefit from the first-to-market advantage. Given the recent rise in partnership activity in this field, and the growing demand for remote diagnostic and therapeutic solutions (mostly influenced by the pandemic), we believe that the digital biomarkers market is likely to grow at a healthy pace over the next decade.
The “Digital Solutions for Biomarkers Market by Content of Solution (Standalone Software Solutions and Combination Offerings), Purpose of Solution (Diagnosis, Early Screening, Monitoring, and Predictive Insights), Type of Biomarker (Cognitive, Idiosyncratic, Physiological, Vocal, and Other Biomarkers), Therapeutic Area (Autoimmune Disorders, Cardiovascular Disorders, Infectious Disorders, Mental Health Problems, Neurological Disorders, Respiratory Disorders, Substance Use Disorders, and Other Disorders), Business Model (B2B and B2C), and by Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2021-2030 ” report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of digital solutions for biomarkers (either commercialized or under development) in the healthcare industry, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:
One of the key objectives of the report was to estimate the existing market size and future opportunity for digital solutions for biomarkers developers over the next decade. Based on multiple parameters, likely adoption trends, and expected price variations for these products, we have provided an informed estimate of the evolution of the market for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity within digital solutions for biomarkers market across [A] content of solution (combination offering of software application + device or AI, and standalone software applications), [B] purpose of solution (diagnosis, early screening, monitoring and predictive insights), [C] type of biomarker (cognitive, idiosyncratic, physiological, vocal, and other biomarkers), [D] therapeutic area (autoimmune disorders, cardiovascular disorders, infectious disorders, mental health problems, neurological disorders, respiratory disorders, substance use disorders, and other disorders), [E] business model (B2B (healthcare providers, payers, employers and pharmaceutical companies) and B2C (patients and caregivers)), and [F] key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of digital solutions for biomarkers market and its likely evolution in the short-mid term and long term.
Chapter 3 provides a general overview of the digital health sector, covering details related to the current and anticipated future trends in this domain, particularly for digital solutions for biomarkers. Further, it highlights the key concepts related to these modern solutions. The chapter also provides an overview of the various product development pathways adopted by the companies engaged in this domain. In addition, it features information on the prevalent Google Trends, during the period 2016-2020 (till December), as well as insights generated from recent news articles related to digital solutions for biomarkers, indicating the increasing popularity of this domain.
Chapter 4 includes a detailed analysis of the current market landscape of over 45 digital solutions for biomarkers, based on current status (approved, marketed, USFDA submission, research and development, proof-of-concept, and discovery), content of solution (combination offering of software application / gaming solution + AI support or device or personal coach, and standalone software / gaming solution ), purpose of solution (diagnosis, early screening, monitoring, and predictive insights), type of biomarker (cognitive, idiosyncratic, molecular, neurophysiological, physiological, respiratory, vocal, and others ), target indication(s), therapeutic area (autoimmune disorders, cardiovascular disorders, infectious disorders, mental health problems, neurological disorders, respiratory disorders, substance use disorders, and other disorders), target population, and prescription requirement. In addition, the chapter highlights the companies engaged in developing digital solutions for biomarkers, along with information on year of establishment, company size, type of business model used (B2B and B2C) and location of headquarters.
Chapter 5 highlights the contemporary market trends in five schematic representations, which include [A] a bubble analysis comparing the leading players engaged in the development of digital solutions for biomarkers, based on various parameters (such as product portfolio strength, type of biomarker and company size), [B] a grid representation illustrating the distribution of the digital solutions for biomarkers based on their current status, content of solution and therapeutic area, [C] an insightful tree map representation of the digital solutions for biomarkers, based on therapeutic area and company size, [D] a world map representation highlighting the regional distribution of developer companies, and [E] a comparative grid representation to highlight the current and likely future market landscape based on status of development, type of biomarker and therapeutic area.
Chapter 6 features elaborate profiles of prominent players that are either currently engaged in developing or have developed digital solutions for biomarkers. Each company profile features a brief overview of the company (with information on its year of establishment, number of employees, location of headquarters and key members of the executive team), details related to their respective product portfolio, recent developments and an informed future outlook.
Chapter 7 presents a detailed product competitiveness analysis of digital solutions for biomarkers taking into consideration several parameters, such as current status, content of solution, purpose of solution, therapeutic area, and prescription requirement.
Chapter 8 provides an analysis of the recent global events (summits / forums / conferences / annual meetings) that were organized for stakeholders engaged in this domain, highlighting the evolution of discussion topics related to digital solutions for biomarkers. The chapter also includes details on type of event, regional distribution, emerging agendas, popular organizers, and most active industry and non-industry players.
Chapter 9 features an elaborate analysis of the investments, including seed financing, venture capital financing, debt financing, grants / awards, made at various stages of development in companies that are engaged in this field, during the period 2012-2020 (till September), highlighting the growing interest of the venture capital community and other strategic investors, in this domain.
Chapter 10 features an in-depth analysis and discussion on the various partnerships inked between the players in this market, during the period, 2014 and 2020 (till September), covering marketing and distribution agreements, mergers / acquisitions, pilot programs, product / technology integration agreements, product / technology licensing agreements, product development agreements, product development and commercialization agreements, product evaluation agreements, and research and development agreements.
Chapter 11 highlights the analysis of the various digital solutions for biomarkers focused initiatives carried out by big pharma players (out of top 25 established pharmaceutical players), featuring [A] an analysis highlighting information on clinical research activity, funding, partnership activity, research publications, and participation in conferences, and [B] a spider web representation of the individual competitiveness of the initiatives of big pharma players based on multiple relevant parameters.
Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of digital solutions for biomarkers market till 2030. We have segmented the market across [A] content of solution (combination offering of software application + device or AI, standalone software applications and other contents of solutions), [B] purpose of solution (diagnosis, early screening, monitoring and predictive insights), [C] type of biomarker (cognitive, idiosyncratic, physiological, vocal, and other biomarkers), [D] therapeutic area (autoimmune disorders, cardiovascular disorders, infectious disorders, mental health problems, neurological disorders, respiratory disorders, substance use disorders, and other disorders), [E] business model (B2B (healthcare providers, payers, employers and pharmaceutical companies) and B2C (patients and caregivers)), and [F] key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Rest of the World).
Chapter 13 highlights how the recent COVID-19 outbreak is likely to impact the overall digital biomarkers market. In addition, it features a brief discussion on the key initiatives undertaken by big pharma players to overcome the challenges faced due the pandemic
Chapter 14 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the digital solutions for biomarkers market.
Chapter 15 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Edouard Gasser (Co-Founder and Chief Executive Officer, Tilak Healthcare), and Michael Seggev (Chief Commercial Officer, Vocalis Health).
Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1 Chapter Overview
3.2. Overview of Digital Biomarkers
3.2.1 Classification of Digital Biomarkers
3.2.2 Key Advantages and Limitations
3.3. Digital Biomarker-related Product Development and Commercialization Path
3.3.1. Product Discovery and Development
3.3.2. Validation and Regulatory Submissions
3.3.3. Distribution and Marketing
3.4. Prevalent Trends Related to Digital Biomarkers
3.4.1. Emerging Focus Areas
3.4.2. Key Historical Trends
3.4.3. Geographical Activity
4 . MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Solutions for Biomarkers: Overall Market Landscape
4.2.1. Analysis by Current Status
4.2.2. Analysis by Content of Solution
4.2.3. Analysis by Purpose of Solution
4.2.4. Analysis by Type of Biomarker
4.2.5. Analysis by Target Indication(s)
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Target Population
4.2.8. Analysis by Prescription Requirement
4.3. Digital Solutions for Biomarkers: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Type of Business Model Used
4.3.4 Analysis by Location of Headquarters
4.4. Leading Developers: Analysis by Number of Digital Solutions for Biomarker
4.5. Digital Solutions for Biomarkers: Information on Additional Players
5. KEY INSIGHTS
5.1. Chapter Overview
5.2. 4D Bubble Analysis: Analysis by Portfolio Strength, Type of Biomarker and Company Size
5.3. Grid Representation: Analysis by Current Status, Content of Solution and Therapeutic Area
5.4. Treemap Representation: Analysis by Therapeutic Area and Company Size
5.5. World Map Representation: Analysis by Location of Headquarters
5.6. Current and Future Market Landscape Trends Analysis
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Acculi Labs
6.2.1 Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Canary Health Technologies
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Empatica
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5 IXICO
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Kinsa
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Progentec Diagnostics
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Vocalis Health
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3 Recent Developments and Future Outlook
7. PRODUCT COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Key Parameters and Methodology
7.3. Product Competitiveness Analysis
7.3.1. Product Competitiveness Analysis: Idiosyncratic Biomarkers
7.3.2. Product Competitiveness Analysis: Physiological Biomarkers
7.3.3. Product Competitiveness Analysis: Vocal Biomarkers
7.3.4. Product Competitiveness Analysis: Other Biomarkers
8 . GLOBAL EVENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Global Events Related to Digital Biomarkers
8.3.1. Analysis by Year of Occurrence
8.3.2. Analysis by Event Platform
8.3.3. Analysis by Geography
8.3.4. Analysis by Type of Event
8.3.5. Evolutionary Trend in Key Agenda / Event Agenda
8.3.6. Most Active Event Organizers
8.3.7. Most Active Players in Terms of Event Participation
8.3.8. Analysis by Seniority Level of Participants
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Digital Solutions for Biomarkers: Funding and Investment Analysis
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Type of Biomarker
9.3.5. Analysis by Therapeutic Area
9.3.6. Analysis by Geography
9.3.7. Most Active Players: Analysis by Number of Instances
9.3.8. Most Active Players: Analysis by Amount Invested
9.3.9. Most Active Investors: Analysis by Number of Instances
9.4 Concluding Remarks
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Digital Solutions for Biomarkers: Recent Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.2.1. Analysis by Type of Partnership and Year of Partnership
10.3.2.2. Analysis by Type of Partnership and Company Size
10.3.3. Analysis by Type of Partner
10.3.3.1. Analysis by Type of Partner and Year of Partnership
10.3.3.2. Analysis by Type of Partner and Type of Partnership
10.3.3.3. Analysis by Type of Partner and Company Size
10.3.4. Analysis by Type of Biomarker
10.3.4.1. Analysis by Type of Biomarker and Year of Partnership
10.3.4.2. Analysis by Type of Biomarker and Type of Partnership
10.3.5. Analysis by Therapeutic Area
10.3.5.1. Analysis by Therapeutic Area and Year of Partnership
10.3.5.2 Analysis by Therapeutic Area and Type of Partner
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.3.7. Regional Analysis
10.3.8. Intercontinental and Intracontinental Agreements
11. BIG PHARMA INITIATIVES
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Digital Biomarker-related Initiatives of Big Pharma Players
11.3.1. Clinical Research Activity
11.3.2. Partnership Activity
11.3.3. Funding and Investments
11.3.4. Participation in Global Events
11.3.5. Research Publications
11.4. Benchmark Analysis of Big Pharmaceutical Players
11.4.1. Spider Web Analysis: Company A
11.4.2. Spider Web Analysis: Company B
11.4.3. Spider Web Analysis: Company C
11.4.4. Spider Web Analysis: Company D
11.4.5. Spider Web Analysis: Company E
11.4.6. Spider Web Analysis: Company F
11.4.8. Spider Web Analysis: Company G
11.4.8. Spider Web Analysis: Company H
11.4.9. Spider Web Analysis: Company I
11.4.10. Spider Web Analysis: Company J
11.4.11. Spider Web Analysis: Company K
11.4.12. Spider Web Analysis: Company L
11.4.13. Spider Web Analysis: Company M
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Digital Solutions for Biomarkers Market, 2021-2030
12.4. Digital Solutions for Biomarkers Market: Distribution by Content of Solution
12.4.1. Digital Solutions for Biomarkers Market for Standalone Software Applications, 2021-2030
12.4.2. Digital Solutions for Biomarkers Market for Combination Offering (Software Application + AI Support), 2021-2030
12.4.3. Digital Solutions for Biomarkers Market for Combination Offering (Software Application + Device), 2021-2030
12.4.4. Digital Solutions for Biomarkers Market for Combination Offering (Software Application + AI Support + Device), 2021-2030
12.4.5. Digital Solutions for Biomarkers Market for Other Content of Solutions, 2021-2030
12.5. Digital Solutions for Biomarkers Market: Distribution by Purpose of Solution
12.5.1. Digital Solutions for Biomarkers Market for Diagnosis, 2021-2030
12.5.2. Digital Solutions for Biomarkers Market for Early Screening, 2021-2030
12.5.3. Digital Solutions for Biomarkers Market for Monitoring, 2021-2030
12.5.4. Digital Solutions for Biomarkers Market for Predictive Insights, 2021-2030
12.6. Digital Solutions for Biomarkers Market: Distribution by Type of Biomarker
12.6.1. Digital Solutions for Cognitive Biomarkers Market, 2021-2030
12.6.2. Digital Solutions for Idiosyncratic Biomarkers Market, 2021-2030
12.6.3. Digital Solutions for Physiological Biomarkers Market, 2021-2030
12.6.4. Digital Solutions for Vocal Biomarkers Market, 2021-2030
12.6.5. Digital Solutions for Other Biomarkers Market, 2021-2030
12.7. Digital Solutions for Biomarkers Market: Distribution by Therapeutic Area
12.7.1. Digital Solutions for Biomarkers Market for Autoimmune Disorders, 2021-2030
12.7.2. Digital Solutions for Biomarkers Market for Cardiovascular Disorders, 2021-2030
12.7.3. Digital Solutions for Biomarkers Market for Infectious Disorders, 2021-2030
12.7.4. Digital Solutions for Biomarkers Market for Mental Health Problems, 2021-2030
12.7.5. Digital Solutions for Biomarkers Market for Neurological Disorders, 2021-2030
12.7.6. Digital Solutions for Biomarkers Market for Respiratory Disorders, 2021-2030
12.7.7. Digital Solutions for Biomarkers Market for Substance Use Disorders, 2021-2030
12.7.8. Digital Solutions for Biomarkers Market for Other Disorders, 2021-2030
12.8. Digital Solutions for Biomarkers Market: Distribution by Business Model
12.8.1. Digital Solutions for Biomarkers Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2021-2030
12.8.2. Digital Solutions for Biomarkers Market for B2C Model (Patients and Caregivers), 2021-2030
12.9. Digital Solutions for Biomarkers Market: Distribution by Key Geographical Regions
12.9.1. Digital Solutions for Biomarkers Market in North America, 2021-2030
12.9.2. Digital Solutions for Biomarkers Market in Europe, 2021-2030
12.9.3. Digital Solutions for Biomarkers Market in Asia-Pacific, 2021-2030
12.9.4. Digital Solutions for Biomarkers Market in Middle East and North Africa (MENA), 2021-2030
12.9.5. Digital Solutions for Biomarkers Market in Rest of the World, 2021-2030
12.10. Concluding Remarks
13. IMPACT OF COVID-19 PANDEMIC ON DIGITAL SOLUTIONS FOR BIOMARKERS MARKET
13.1. Chapter Overview
13.2. Impact of COVID-19 Pandemic on Digital Solutions for Biomarkers Market
13.2.1. Impact on Future Market Opportunity for Digital Solutions for Biomarkers
13.3. Current Opinions and Key Initiatives of Key Players
13.4. Recuperative Strategies for Developer Businesses
13.4.1. Strategies for Implementation in the Short / Mid Term
13.4.2. Strategies for Implementation in the Long Term
14. CONCLUSION
14.1. Chapter Overview
14.2. Key Takeaways
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Tilak Healthcare
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Edouard Gasser, Co-Founder and Chief Executive Officer
15.3. Vocalis Health
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Michael Seggev, Chief Commercial Officer
16. APPENDIX I: TABULATED DATA
17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION
Figure 3.1 Types of Digital Biomarkers
Figure 3.2 Types of Biomarkers / Signals captured by Digital Solutions for Biomarkers
Figure 3.3 Key Advantages and Limitations for Digital Biomarkers
Figure 3.4 Google News: Emerging Focus Areas
Figure 3.5 Google Trends: Historical Timeline
Figure 3.6 Google Trends: Geographical Activity
Figure 4.1 Digital Solutions for Biomarkers: Distribution by Current Status
Figure 4.2 Digital Solutions for Biomarkers: Distribution by Launch Year
Figure 4.3 Digital Solutions for Biomarkers: Distribution by Content of Solution
Figure 4.4 Digital Solutions for Biomarkers: Distribution by Purpose of Solution
Figure 4.5 Digital Solutions for Biomarkers: Distribution by Type of Biomarker
Figure 4.6 Digital Solutions for Biomarkers: Distribution by Purpose of Solution and Type of Biomarker
Figure 4.7 Digital Solutions for Biomarkers: Distribution by Target Indication(s)
Figure 4.8 Digital Solutions for Biomarkers: Distribution by Therapeutic Area
Figure 4.9 Digital Solutions for Biomarkers: Distribution by Target Population
Figure 4.10 Digital Solutions for Biomarkers: Distribution by Prescription Requirement
Figure 4.11 Digital Solutions for Biomarkers Developers: Distribution by Year of Establishment
Figure 4.12 Digital Solutions for Biomarkers Developers: Distribution by Company Size
Figure 4.13 Digital Solutions for Biomarkers Developers: Distribution by Type of Business Model Used
Figure 4.14 Digital Solutions for Biomarkers Developers: Distribution by Location of Headquarters
Figure 4.15 Digital Solutions for Biomarkers Developers: Leading Developers Based on Number of Digital Solutions for Biomarkers
Figure 5.1 4D Bubble Analysis: Distribution by Portfolio Strength, Type of Biomarker and Company Size
Figure 5.2 Grid Representation: Analysis by Current Status, Content of Solution and Therapeutic Area
Figure 5.3 Tree Map Representation: Analysis by Therapeutic Area and Company Size
Figure 5.4 World Map Representation: Analysis by Location of Headquarters
Figure 5.5 Current and Future Market Landscape Trend Analysis: Distribution by Status of Development, Type of Biomarker and Therapeutic Area
Figure 7.1 Product Competitiveness Analysis: Idiosyncratic Biomarkers
Figure 7.2 Product Competitiveness Analysis: Physiological Biomarkers
Figure 7.3 Product Competitiveness Analysis: Vocal Biomarkers
Figure 7.4 Product Competitiveness Analysis: Other Biomarkers
Figure 8.1 Global Events Analysis: Cumulative Year-Wise Trend, 2016-H1 2021
Figure 8.2 Global Events Analysis: Distribution by Event Platform
Figure 8.3 Global Events Analysis: Distribution by Geography
Figure 8.4 Global Events Analysis: Distribution by Location
Figure 8.5 Global Events Analysis: Distribution by Type of Event
Figure 8.6 Global Events Analysis: Evolutionary Trend of Key Agendas
Figure 8.7 Global Events Analysis: Historical Trend of Key Agendas, 2016-H1 2021
Figure 8.8 Global Events Analysis: Most Active Event Organizers
Figure 8.9 Global Events Analysis: Most Active Industry Players Based on Event Participation
Figure 8.10 Global Events Analysis: Most Active Non-Industry Players Based on Event Participation
Figure 8.11 Global Event Analysis: Distribution by Designations of Event Participants
Figure 9.1 Funding and Investments Analysis: Distribution of Recipient Companies by Year of Establishment and Type of Funding
Figure 9.2 Funding and Investments Analysis: Cumulative Year-wise Distribution of Funding Instances, 2012 – Q3 2020
Figure 9.3 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), 2012 - Q3 2020
Figure 9.4 Funding and Investments Analysis: Distribution of Instances by Type of Funding, 2012 - Q3 2020
Figure 9.5 Funding and Investments Analysis: Year-Wise Distribution by Type of Funding, 2012 - Q3 2020
Figure 9.6 Funding and Investments Analysis: Year-Wise Distribution by Type of Funding and Amount Invested (USD Million), 2012 - Q3 2020
Figure 9.7 Funding and Investments Analysis: Summary of Amount Invested (USD Million), 2012 - Q3 2020
Figure 9.8 Funding and Investments Analysis: Distribution of Instances by Type of Biomarker, 2012 - Q3 2020
Figure 9.9 Funding and Investments Analysis: Distribution of Total Amount Invested by Type of Biomarker, 2012 – Q3 2020 (USD Million)
Figure 9.10 Funding and Investments Analysis: Year-Wise Distribution of Instances by Type of Biomarker, 2012 – Q3 2020
Figure 9.11 Funding and Investments Analysis: Cumulative Amount Invested by Type of Biomarker, 2012 - Q3 2020 (USD Million)
Figure 9.12 Funding and Investments Analysis: Distribution of Instances by Therapeutic Area, 2012 – Q3 2020
Figure 9.13 Funding and Investments Analysis: Distribution of Total Amount Invested by Therapeutic Area, 2012 – Q3 2020 (USD Million)
Figure 9.14 Funding and Investment Analysis: Distribution by Geography
Figure 9.15 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, 2012 – Q3 2020 (USD Million)
Figure 9.16 Funding and Investment Analysis: Most Active Players Based on Number of Funding Instances, 2012 – Q3 2020
Figure 9.17 Funding and Investment Analysis: Most Active Players Based on Total Amount Raised, 2012 – Q3 2020 (USD Million)
Figure 9.18 Funding and Investment Analysis: Most Active Investors Based on Number of Funding Instances
Figure 9.19 Funding and Investment Summary, 2012 – Q3 2020 (USD Million)
Figure 10.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2014 - Q3 2020
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.6 Partnerships and Collaborations: Year-Wise Trend by Type of Partner
Figure 10.7 Partnerships and Collaborations: Distribution by Type of Partner and Type of Partnership
Figure 10.8 Partnerships and Collaborations: Distribution by Type of Partner and Company Size
Figure 10.9 Partnerships and Collaborations: Distribution by Type of Biomarker
Figure 10.10 Partnerships and Collaborations: Year-Wise Trend by Type of Biomarker
Figure 10.11 Partnerships and Collaborations: Distribution by Type of Biomarker and Type of Partnership
Figure 10.12 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 10.13 Partnerships and Collaborations: Year-Wise Trend by Therapeutic Area
Figure 10.14 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partner
Figure 10.15 Most Active Players: Distribution by Number of Partnerships
Figure 10.16 Partnerships and Collaborations: Regional Distribution
Figure 10.17 Partnerships and Collaborations: Country-wise Distribution
Figure 10.18 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 11.1 Big Pharma Initiatives: Heat Map Distribution of Top Pharmaceutical Companies
Figure 11.2 Big Pharma Initiatives: Distribution by Number of Clinical Trials
Figure 11.3 Big Pharma Initiatives: Distribution by Number of Collaborations
Figure 11.4 Big Pharma Initiatives: Distribution by Amount of Funding (USD Million)
Figure 11.5 Big Pharma Initiatives: Distribution by Participation in Global Events
Figure 11.6 Big Pharma Initiatives: Distribution by Number of Research Publications
Figure 11.7 Spider Web Analysis: Company A
Figure 11.8 Spider Web Analysis: Company B
Figure 11.9 Spider Web Analysis: Company C
Figure 11.10 Spider Web Analysis: Company D
Figure 11.11 Spider Web Analysis: Company E
Figure 11.12 Spider Web Analysis: Company F
Figure 11.13 Spider Web Analysis: Company G
Figure 11.14 Spider Web Analysis: Company H
Figure 11.15 Spider Web Analysis: Company I
Figure 11.16 Spider Web Analysis: Company J
Figure 11.17 Spider Web Analysis: Company K
Figure 11.18 Spider Web Analysis: Company L
Figure 11.19 Spider Web Analysis: Company M
Figure 12.1 Overall Digital Solutions for Biomarkers Market, 2021-2030 (USD Million)
Figure 12.2 Global Digital Solutions for Biomarkers Market: Distribution by Content of Solution, 2021 and 2030
Figure 12.3 Digital Solutions for Biomarkers Market for Standalone Software Applications, 2021-2030 (USD Million)
Figure 12.4 Digital Solutions for Biomarkers Market for Combination Offerings (Software Application + AI Support), 2021-2030 (USD Million)
Figure 12.5 Digital Solutions for Biomarkers Market for Combination Offerings (Software Application + Device), 2021-2030 (USD Million)
Figure 12.6 Digital Solutions for Biomarkers Market for Other Content of Solutions, 2021-2030 (USD Million)
Figure 12.7 Global Digital Solutions for Biomarkers Market: Distribution by Purpose of Solution, 2021 and 2030
Figure 12.8 Digital Solutions for Biomarkers Market for Diagnosis, 2021-2030 (USD Million)
Figure 12.9 Digital Solutions for Biomarkers Market for Early Screening, 2021-2030 (USD Million)
Figure 12.10 Digital Solutions for Biomarkers Market for Monitoring, 2021-2030 (USD Million)
Figure 12.11 Digital Solutions for Biomarkers Market for Predictive Insights, 2021-2030 (USD Million)
Figure 12.13 Global Digital Solutions for Biomarkers Market: Distribution by Type of Biomarker, 2021 and 2030
Figure 12.14 Digital Solutions for Cognitive Biomarkers Market, 2021-2030 (USD Million)
Figure 12.15 Digital Solutions for Idiosyncratic Biomarkers Market, 2021-2030 (USD Million)
Figure 12.16 Digital Solutions for Physiological Biomarkers Market, 2021-2030 (USD Million)
Figure 12.17 Digital Solutions for Vocal Biomarkers Market, 2021-2030 (USD Million)
Figure 12.18 Digital Solutions for Other Biomarkers Market, 2021-2030 (USD Million)
Figure 12.19 Global Digital Solutions for Biomarkers Market: Distribution by Therapeutic Area, 2021 and 2030
Figure 12.20 Digital Solutions for Biomarkers Market for Autoimmune Disorders, 2021-2030 (USD Million)
Figure 12.21 Digital Solutions for Biomarkers Market for Cardiovascular Disorders, 2021-2030 (USD Million)
Figure 12.22 Digital Solutions for Biomarkers Market for Infectious Disorders, 2021-2030 (USD Million)
Figure 12.23 Digital Solutions for Biomarkers Market for Mental Health Problems, 2021-2030 (USD Million)
Figure 12.24 Digital Solutions for Biomarkers Market for Neurological Disorders, 2021-2030 (USD Million)
Figure 12.25 Digital Solutions for Biomarkers Market for Respiratory Disorders, 2021-2030 (USD Million)
Figure 12.26 Digital Solutions for Biomarkers Market for Substance Use Disorders, 2021-2030 (USD Million)
Figure 12.27 Digital Solutions for Biomarkers Market for Other Disorders, 2021-2030 (USD Million)
Figure 12.28 Global Digital Solutions for Biomarkers Market: Distribution by Business Model, 2021 and 2030
Figure 12.29 Digital Solutions for Biomarkers Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2021-2030 (USD Million)
Figure 12.30 Digital Solutions for Biomarkers Market for B2C Model (Patients and Caregivers), 2021-2030 (USD Million)
Figure 12.31 Global Digital Solutions for Biomarkers Market: Distribution by Geography, 2021 and 2030
Figure 12.32 Digital Solutions for Biomarkers Market in North America, 2021-2030 (USD Million)
Figure 12.33 Digital Solutions for Biomarkers Market in Europe, 2021-2030 (USD Million)
Figure 12.34 Digital Solutions for Biomarkers Market in Asia-Pacific, 2021-2030 (USD Million)
Figure 12.35 Digital Solutions for Biomarkers Market in Middle East and North Africa, 2021-2030 (USD Million)
Figure 12.36 Digital Solutions for Biomarkers Market in Rest of the World, 2021-2030 (USD Million)
Figure 12.37 Global Digital Solutions for Biomarkers Market: Conservative, Base and Optimistic Scenarios, 2021, 2025 and 2030 (USD Million)
Figure 13.1 Digital Solutions for Biomarkers Market, 2021-2030: COVID-19 Impact Scenario (USD Billion)
Figure 13.2 Key Players in Digital Solutions for Biomarkers Domain to Target COVID-19 Pandemic
Figure 14.1 Concluding Remarks: Current Market Landscape-I
Figure 14.2 Concluding Remarks: Current Market Landscape-II
Figure 14.3 Concluding Remarks: Global Events Analysis
Figure 14.4 Concluding Remarks: Funding and Investments Analysis
Figure 14.5 Concluding Remarks: Partnerships and Collaborations
Figure 14.6 Concluding Remarks: Big Pharma Initiatives
Figure 14.7 Concluding Remarks: Market Forecast
Table 4.1 Digital Solutions for Biomarkers: Information on Current Status and Launch Year
Table 4.2 Digital Solutions for Biomarkers: Information on Content of Solution
Table 4.3 Digital Solutions for Biomarkers: Information on Purpose of Solution and Type of Biomarker
Table 4.4 Digital Solutions for Biomarkers: Information on Target Indication(s) and Therapeutic Area
Table 4.5 Digital Solutions for Biomarkers: Information on Target Population and Prescription Requirement
Table 4.6 Digital Solutions for Biomarkers: List of Developers
Table 6.1 Digital Solutions for Biomarkers: List of Companies Profiled
Table 6.2 Acculi Labs: Company Overview
Table 6.3 Acculi Labs: Digital Solutions for Biomarkers Portfolio
Table 6.4 Acculi Labs: Recent Developments and Future Outlook
Table 6.5 Canary Health Technologies: Company Overview
Table 6.6 Canary Health Technologies: Digital Solutions for Biomarkers Portfolio
Table 6.7 Canary Health Technologies: Recent Developments and Future Outlook
Table 6.8 Empatica: Company Overview
Table 6.9 Empatica: Digital Solutions for Biomarkers Portfolio
Table 6.10 Empatica: Recent Developments and Future Outlook
Table 6.11 IXICO: Company Overview
Table 6.12 IXICO: Digital Solutions for Biomarkers Portfolio
Table 6.13 IXICO: Recent Developments and Future Outlook
Table 6.14 Kinsa: Company Overview
Table 6.15 Kinsa: Digital Solutions for Biomarkers Portfolio
Table 6.16 Kinsa: Recent Developments and Future Outlook
Table 6.17 Progentec Diagnostics: Company Overview
Table 6.18 Progentec Diagnostics: Digital Solutions for Biomarkers Portfolio
Table 6.19 Progentec Diagnostics: Recent Developments and Future Outlook
Table 6.20 Spirosure: Company Overview
Table 6.21 Spirosure: Digital Solutions for Biomarkers Portfolio
Table 6.22 Spirosure: Recent Developments and Future Outlook
Table 6.23 Vocalis Health: Company Overview
Table 6.24 Vocalis Health: Digital Solutions for Biomarkers Portfolio
Table 6.25 Vocalis Health: Recent Developments and Future Outlook
Table 8.1 List of Events related to Digital Solutions for Biomarkers
Table 9.1 Digital Solutions for Biomarkers: Funding and Investments, Information on Year of Investment, Type of Funding, Amount invested and Name of the Investor, 2012 - Q3 2020
Table 9.2 Digital Solutions for Biomarkers: Funding and Investments, Information on Year of Establishment, Location of Headquarters of Recipients, Type of Biomarker, and Therapeutic Area
Table 10.1 Digital Solutions for Biomarkers: List of Collaborations, 2014 - Q3 2020
Table 10.2 Digital Solutions for Biomarkers: Partnerships and Collaborations, Information on Type of Partner and Type of Agreement (Region-wise and Geography-wise), 2014 - Q3 2020
Table 16.1 Digital Solutions for Biomarkers: Distribution by Current Status
Table 16.2 Digital Solutions for Biomarkers: Distribution by Launch Year
Table 16.3 Digital Solutions for Biomarkers: Distribution by Content of Solution
Table 16.4 Digital Solutions for Biomarkers: Distribution by Purpose of Solution
Table 16.5 Digital Solutions for Biomarkers: Distribution by Type of Biomarker
Table 16.6 Digital Solutions for Biomarkers: Distribution by Purpose of Solution and Type of Biomarker
Table 16.7 Digital Solutions for Biomarkers: Distribution by Target Indication(s)
Table 16.8 Digital Solutions for Biomarkers: Distribution by Therapeutic Area
Table 16.9 Digital Solutions for Biomarkers: Distribution by Target Population
Table 16.10 Digital Solutions for Biomarkers: Distribution by Prescription Requirement
Table 16.11 Digital Solutions for Biomarkers Developers: Distribution by Year of Establishment
Table 16.12 Digital Solutions for Biomarkers Developers: Distribution by Company Size
Table 16.13 Digital Solutions for Biomarkers Developers: Distribution by Type of Business Model Used
Table 16.14 Digital Solutions for Biomarkers Developers: Distribution by Location of Headquarters
Table 16.15 Digital Solutions for Biomarkers Developers: Leading Developers Based on Number of Digital Solutions for Biomarkers
Table 16.16 4D Bubble Analysis: Analysis by Portfolio Strength, Type of Biomarker and Company Size
Table 16.17 Grid Representation: Analysis by Current Status, Content of Solution and Therapeutic Area
Table 16.18 Tree Map Representation: Analysis by Therapeutic Area and Company Size
Table 16.19 World Map Representation: Analysis by Location of Headquarters
Table 16.20 Current and Future Market Landscape Trends Analysis: Distribution by Current Status, Type of Biomarker and Therapeutic Area
Table 16.21 Global Events Analysis: Cumulative Half Year-Wise Trend, 2016 – H1 2021
Table 16.22 Global Events Analysis: Distribution by Event Platform
Table 16.23 Global Events Analysis: Distribution by Geography
Table 16.24 Global Events Analysis: Distribution by Location
Table 16.25 Global Events Analysis: Distribution by Type of Event
Table 16.26 Global Events Analysis: Most Active Event Organizers
Table 16.27 Global Events Analysis: Most Active Industry Players Based on Event Participation
Table 16.28 Global Events Analysis: Most Active Non-Industry Players Based on Event Participation
Table 16.29 Global Events Analysis: Distribution by Designations of Event Participants
Table 16.30 Funding and Investments Analysis: Distribution of Recipient Companies by Year of Establishment and Type of Funding
Table 16.31 Funding and Investments Analysis: Cumulative Year-wise Distribution of Funding Instances by Year, 2012 – Q3 2020
Table 16.32 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), 2012 - Q3 2020
Table 16.33 Funding and Investments Analysis: Distribution of Instances by Type of Funding, 2012 - Q3 2020
Table 16.34 Funding and Investments Analysis: Year-Wise Distribution by Type of Funding, 2012 - Q3 2020
Table 16.35 Funding and Investments Analysis: Year-Wise Distribution by Type of Funding and Funding Amount Invested, 2012 - Q3 2020 (USD Million)
Table 16.36 Funding and Investments Analysis: Summary of Amount Invested, 2012 - Q3 2020 (USD Million)
Table 16.37 Funding and Investments Analysis: Distribution of Instances by Type of Biomarker, 2012 - Q3 2020
Table 16.38 Funding and Investments Analysis: Distribution of Total Amount Invested by Type of Biomarker, 2012 – Q3 2020 (USD Million)
Table 16.39 Funding and Investments Analysis: Year-Wise Distribution of Instances by Type of Biomarker, 2012 – Q3 2020
Table 16.40 Funding and Investments Analysis: Cumulative Amount Invested by Type of Biomarker, 2012 - Q3 2020 (USD Million)
Table 16.41 Funding and Investments Analysis: Distribution of Instances by Therapeutic Area, 2012 – Q3 2020 (USD Million)
Table 16.42 Funding and Investments Analysis: Distribution of Total Amount Invested by Therapeutic Area, 2012 – Q3 2020 (USD Million)
Table 16.43 Funding and Investment Analysis: Distribution by Geography
Table 16.44 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, 2012 – Q3 2020 (USD Million)
Table 16.45 Funding and Investment Analysis: Most Active Players Based on Number of Funding Instances, 2012 – Q3 2020
Table 16.46 Funding and Investment Analysis: Most Active Players Based on Total Amount Raised (USD Million), 2012 – Q3 2020 (USD Million)
Table 16.47 Funding and Investment Analysis: Most Active Investors Based on Number of Funding Instances
Table 16.48 Funding and Investment Summary, 2012 – Q3 2020 (USD Million)
Table 16.49 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2014 – Q3
Table 16.50 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.51 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Table 16.52 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 16.53 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.54 Partnerships and Collaborations: Year-Wise Trend by Type of Partner
Table 16.55 Partnerships and Collaborations: Distribution by Type of Partner and Type of Partnership
Table 16.56 Partnerships and Collaborations: Distribution by Type of Partner and Company Size
Table 16.57 Partnerships and Collaborations: Distribution by Type of Biomarker
Table 16.58 Partnerships and Collaborations: Year-Wise Trend by Type of Biomarker
Table 16.59 Partnerships and Collaborations: Distribution by Type of Biomarker and Type of Partnership
Table 16.60 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 16.61 Partnerships and Collaborations: Year-Wise Trend by Therapeutic Area
Table 16.62 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partner
Table 16.63 Most Active Players: Distribution by Number of Partnerships
Table 16.64 Partnerships and Collaborations: Regional Distribution
Table 16.65 Partnerships and Collaborations: Country-wise Distribution
Table 16.66 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.67 Big Pharma Initiatives: Heat Map Distribution of Top Pharmaceutical Companies
Table 16.68 Big Pharma Initiatives: Distribution by Number of Clinical Trials
Table 16.69 Big Pharma Initiatives: Distribution by Number of Collaborations
Table 16.70 Big Pharma Initiatives: Distribution by Amount of Funding (USD Million)
Table 16.71 Big Pharma Initiatives: Distribution by Participation in Global Events
Table 16.72 Big Pharma Initiatives: Distribution by Number of Research Publications
Table 16.73 Overall Digital Solutions for Biomarkers Market: Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.74 Global Digital Solutions for Biomarkers Market: Distribution by Content of Solution, 2021 and 2030
Table 16.75 Digital Solutions for Biomarkers Market for Standalone Software Applications, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.76 Digital Solutions for Biomarkers Market for Combination Offerings (Software Application + AI Support), Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.77 Digital Solutions for Biomarkers Market for Combination Offerings (Software Application + Device), Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.78 Digital Solutions for Biomarkers Market for Other Content of Solutions, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.79 Global Digital Solutions for Biomarkers Market: Distribution by Purpose of Solution, 2021 and 2030
Table 16.80 Digital Solutions for Biomarkers Market for Diagnosis, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.81 Digital Solutions for Biomarkers Market for Early Screening, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.82 Digital Solutions for Biomarkers Market for Monitoring, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.83 Digital Solutions for Biomarkers Market for Predictive Insights, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.84 Global Digital Solutions for Biomarkers Market: Distribution by Type of Biomarker, 2021 and 2030
Table 16.85 Digital Solutions for Cognitive Biomarkers Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.86 Digital Solutions for Idiosyncratic Biomarkers Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.87 Digital Solutions for Physiological Biomarkers Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.88 Digital Solutions for Vocal Biomarkers Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.89 Digital Solutions for Other Biomarkers Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.90 Global Digital Solutions for Biomarkers Market: Distribution by Therapeutic Area, 2021 and 2030
Table 16.91 Digital Solutions for Biomarkers Market for Autoimmune Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.92 Digital Solutions for Biomarkers Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.93 Digital Solutions for Biomarkers Market for Infectious Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.94 Digital Solutions for Biomarkers Market for Mental Health Problems, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.95 Digital Solutions for Biomarkers Market for Neurological Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.96 Digital Solutions for Biomarkers Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.97 Digital Solutions for Biomarkers Market for Substance Use Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.98 Digital Solutions for Biomarkers Market for Other Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.99 Global Digital Solutions for Biomarkers Market: Distribution by Business Model, 2021 and 2030
Table 16.100 Digital Solutions for Biomarkers Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.101 Digital Solutions for Biomarkers Market for B2C Model (Patients and Caregivers), Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.102 Global Digital Solutions for Biomarkers Market: Distribution by Geography, 2021 and 2030
Table 16.103 Digital Solutions for Biomarkers Market in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.104 Digital Solutions for Biomarkers Market in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.105 Digital Solutions for Biomarkers Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.106 Digital Solutions for Biomarkers Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.107 Digital Solutions for Biomarkers Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.108 Global Digital Solutions for Biomarkers Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Conservative, Base and Optimistic Scenarios, 2021, 2025 and 2030 (USD Million)
Table 16.109 Digital Solutions for Biomarkers Market, 2021-2030: COVID-19 Impact Scenario (USD Billion)
The following companies and organizations have been mentioned in the report.
The USD 22.6 billion (by 2030) financial opportunity within the digital solutions for biomarkers market has been analyzed across the following segments:
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES